Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters











Publication year range
1.
Genes Brain Behav ; 20(8): e12773, 2021 11.
Article in English | MEDLINE | ID: mdl-34672075

ABSTRACT

Drugs of abuse, including alcohol and stimulants like cocaine, produce effects that are subject to individual variability, and genetic variation accounts for at least a portion of those differences. Notably, research in both animal models and human subjects point toward reward sensitivity and impulsivity as being trait characteristics that predict relatively greater positive subjective responses to stimulant drugs. Here we describe use of the eight collaborative cross (CC) founder strains and 38 (reversal learning) or 10 (all other tests) CC strains to examine the heritability of reward sensitivity and impulsivity traits, as well as genetic correlations between these measures and existing addiction-related phenotypes. Strains were all tested for activity in an open field and reward sensitivity (intake of chocolate BOOST®). Mice were then divided into two counterbalanced groups and underwent reversal learning (impulsive action and waiting impulsivity) or delay discounting (impulsive choice). CC and founder mice show significant heritability for impulsive action, impulsive choice, waiting impulsivity, locomotor activity, and reward sensitivity, with each impulsive phenotype determined to be non-correlating, independent traits. This research was conducted within the broader, inter-laboratory effort of the Center for Systems Neurogenetics of Addiction (CSNA) to characterize CC and DO mice for multiple, cocaine abuse related traits. These data will facilitate the discovery of genetic correlations between predictive traits, which will then guide discovery of genes and genetic variants that contribute to addictive behaviors.


Subject(s)
Genetic Variation , Impulsive Behavior , Locomotion/genetics , Reward , Substance-Related Disorders/genetics , Animals , Female , Inbreeding , Male , Mice, Inbred C57BL , Mice, Inbred NOD
2.
Addict Biol ; 26(2): e12903, 2021 03.
Article in English | MEDLINE | ID: mdl-32286721

ABSTRACT

In March 2019, a scientific meeting was held at the University of California, Los Angeles (UCLA) Luskin Center to discuss approaches to expedite the translation of neurobiological insights to advances in the treatment of alcohol use disorder (AUD). A guiding theme that emerged was that while translational research in AUD is clearly a challenge, it is also a field ripe with opportunities. Herein, we seek to summarize and disseminate the recommendations for the future of translational AUD research using four sections. First, we briefly review the current landscape of AUD treatment including the available evidence-based treatments and their uptake in clinical settings. Second, we discuss AUD treatment development efforts from a translational science viewpoint. We review current hurdles to treatment development as well as opportunities for mechanism-informed treatment. Third, we consider models of translational science and public health impact. Together, these critical insights serve as the bases for a series of recommendations and future directions. Towards the goal of improving clinical care and population health for AUD, scientists are tasked with bolstering the clinical applicability of their research findings so as to expedite the translation of knowledge into patient care.


Subject(s)
Alcoholism/pathology , Alcoholism/therapy , Translational Research, Biomedical/organization & administration , Alcohol Deterrents/therapeutic use , Clinical Trials as Topic/organization & administration , Cognitive Behavioral Therapy/methods , Humans , Patient-Centered Care/organization & administration , Terminology as Topic , United States
3.
eNeuro ; 2(3)2015.
Article in English | MEDLINE | ID: mdl-26464985

ABSTRACT

Two theories regarding the role for dopamine neurons in learning include the concepts that their activity serves as a (1) mechanism that confers incentive salience onto rewards and associated cues and/or (2) contingency teaching signal reflecting reward prediction error. While both theories are provocative, the causal role for dopamine cell activity in either mechanism remains controversial. In this study mice that either fully or partially lacked NMDARs in dopamine neurons exclusively, as well as appropriate controls, were evaluated for reward-related learning; this experimental design allowed for a test of the premise that NMDA/glutamate receptor (NMDAR)-mediated mechanisms in dopamine neurons, including NMDA-dependent regulation of phasic discharge activity of these cells, modulate either the instrumental learning processes or the likelihood of pavlovian cues to become highly motivating incentive stimuli that directly attract behavior. Loss of NMDARs in dopamine neurons did not significantly affect baseline dopamine utilization in the striatum, novelty evoked locomotor behavior, or consumption of a freely available, palatable food solution. On the other hand, animals lacking NMDARs in dopamine cells exhibited a selective reduction in reinforced lever responses that emerged over the course of instrumental learning. Loss of receptor expression did not, however, influence the likelihood of an animal acquiring a pavlovian conditional response associated with attribution of incentive salience to reward-paired cues (sign tracking). These data support the view that reductions in NMDAR signaling in dopamine neurons affect instrumental reward-related learning but do not lend support to hypotheses that suggest that the behavioral significance of this signaling includes incentive salience attribution.

4.
J Neurosci ; 34(43): 14443-54, 2014 Oct 22.
Article in English | MEDLINE | ID: mdl-25339755

ABSTRACT

For >30 years, positron emission tomography (PET) has proven to be a powerful approach for measuring aspects of dopaminergic transmission in the living human brain; this technique has revealed important relationships between dopamine D2-like receptors and dimensions of normal behavior, such as human impulsivity, and psychopathology, particularly behavioral addictions. Nevertheless, PET is an indirect estimate that lacks cellular and functional resolution and, in some cases, is not entirely pharmacologically specific. To identify the relationships between PET estimates of D2-like receptor availability and direct in vitro measures of receptor number, affinity, and function, we conducted neuroimaging and behavioral and molecular pharmacological assessments in a group of adult male vervet monkeys. Data gathered from these studies indicate that variation in D2-like receptor PET measurements is related to reversal-learning performance and sensitivity to positive feedback and is associated with in vitro estimates of the density of functional dopamine D2-like receptors. Furthermore, we report that a simple behavioral measure, eyeblink rate, reveals novel and crucial links between neuroimaging assessments and in vitro measures of dopamine D2 receptors.


Subject(s)
Blinking/physiology , Corpus Striatum/physiology , Discrimination Learning/physiology , Feedback, Physiological/physiology , Receptors, Dopamine D2/physiology , Animals , Chlorocebus aethiops , Male , Photic Stimulation/methods , Time Factors
5.
Nat Neurosci ; 17(2): 254-61, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24413699

ABSTRACT

µ-opioid receptors (MORs) are necessary for the analgesic and addictive effects of opioids such as morphine, but the MOR-expressing neuronal populations that mediate the distinct opiate effects remain elusive. Here we devised a new conditional bacterial artificial chromosome rescue strategy to show, in mice, that targeted MOR expression in a subpopulation of striatal direct-pathway neurons enriched in the striosome and nucleus accumbens, in an otherwise MOR-null background, restores opiate reward and opiate-induced striatal dopamine release and partially restores motivation to self administer an opiate. However, these mice lack opiate analgesia or withdrawal. We used Cre-mediated deletion of the rescued MOR transgene to establish that expression of the MOR transgene in the striatum, rather than in extrastriatal sites, is needed for the restoration of opiate reward. Our study demonstrates that a subpopulation of striatal direct-pathway neurons is sufficient to support opiate reward-driven behaviors and provides a new intersectional genetic approach to dissecting neurocircuit-specific gene function in vivo.


Subject(s)
Corpus Striatum/cytology , Neural Pathways/physiology , Neurons/physiology , Receptors, Opioid, mu/metabolism , Reward , Analysis of Variance , Animals , Conditioning, Operant/drug effects , Conditioning, Operant/physiology , Disease Models, Animal , Dopamine/metabolism , Enkephalins/genetics , Exploratory Behavior/drug effects , Exploratory Behavior/physiology , Flow Cytometry , Green Fluorescent Proteins/genetics , Green Fluorescent Proteins/metabolism , Mice , Mice, Transgenic , Microdialysis , Morphine/pharmacology , Naloxone/pharmacology , Narcotic Antagonists/pharmacology , Narcotics/pharmacology , Neurons/classification , Neurons/drug effects , Pain/drug therapy , Pain/genetics , Pain Measurement/drug effects , Protein Precursors/genetics , Receptors, Opioid, mu/deficiency , Substance Withdrawal Syndrome/drug therapy
6.
Neuropharmacology ; 76 Pt B: 479-86, 2014 Jan.
Article in English | MEDLINE | ID: mdl-23748054

ABSTRACT

There are broad individual differences in the ability to voluntarily and effortfully suppress motivated, reward-seeking behaviors, and this review presents the hypothesis that these individual differences are relevant to addictive disorders. On one hand, cumulative experience with drug abuse appears to alter the molecular, cellular and circuit mechanisms that mediate inhibitory abilities, leading to increasingly uncontrolled patterns of drug-seeking and -taking. On the other, native inter-individual differences in inhibitory control are apparently a risk factor for aspects of drug-reinforced responding and substance use disorders. In both cases, the behavioral manifestation of poor inhibitory abilities is linked to relatively low striatal dopamine D2-like receptor availability, and evidence is accumulating for a more direct contribution of striatopallidal neurons to cognitive control processes. Mechanistic research is now identifying genes upstream of dopamine transmission that mediate these relationships, as well as the involvement of other neurotransmitter systems, acting alone and in concert with dopamine. The reviewed research stands poised to identify new mechanisms that can be targeted by pharmacotherapies and/or by behavioral interventions that are designed to prevent or treat addictive behaviors and associated behavioral pathology. This article is part of a Special Issue entitled 'NIDA 40th Anniversary Issue'.


Subject(s)
Behavior, Addictive/complications , Behavior, Addictive/psychology , Impulsive Behavior/etiology , Inhibition, Psychological , Reward , Animals , Behavior, Addictive/diagnosis , Cognition Disorders/etiology , Humans , Impulsive Behavior/psychology
7.
Behav Brain Res ; 256: 279-83, 2013 Nov 01.
Article in English | MEDLINE | ID: mdl-23968589

ABSTRACT

Medium-sized spiny neurons (MSNs), the predominant neuronal population of the striatum, are an integral component of the many cortical and limbic pathways associated with reward-related behaviors. A differential role of the D1 receptor-enriched (D1) MSNs of the striatonigral direct pathway, as compared with the D2 receptor-enriched (D2) MSNs of the striatopallidal indirect pathway, in mediating the addictive behaviors associated with cocaine is beginning to emerge. However, whether opioids, well-known analgesics with euphoric properties, similarly induce dissociable signaling adaptations in these neurons remains unclear. Transgenic mice expressing green fluorescent protein (GFP)-labeled D1 or D2 neurons were implanted with intravenous jugular catheters. Mice learned to self-administer 0.1mg/kg/infusion of the opioid remifentanil during 2h sessions over 13 contiguous days. Thereafter, the electrophysiological properties of D1- and D2-MSNs in the shell region of the nucleus accumbens (NAc) were assessed. We found that prior opioid exposure did not alter the basic membrane properties nor the kinetics or amplitude of miniature excitatory postsynaptic currents (mEPSCs). However, when challenged with the mu opioid receptor (µOR) agonist DAMGO, the characteristic inhibitory profile of this receptor was altered. DAMGO inhibited the frequency of mEPSCs in D1-MSNs from control mice receiving saline and in D2-MSNs from mice exposed to remifentanil or saline, but this inhibitory profile was reduced in D1-MSNs from mice receiving remifentanil. Remifentanil exposure also altered the probability of glutamate release onto D1-, but not D2-MSNs. Together these results suggest a D1-pathway specific effect associated with the acquisition of opioid-seeking behaviors.


Subject(s)
Corpus Striatum/drug effects , Corpus Striatum/physiopathology , GABAergic Neurons/drug effects , GABAergic Neurons/physiology , Opioid-Related Disorders/physiopathology , Animals , Corpus Striatum/cytology , Enkephalin, Ala(2)-MePhe(4)-Gly(5)-/pharmacology , Excitatory Postsynaptic Potentials/drug effects , Excitatory Postsynaptic Potentials/physiology , Female , GABAergic Neurons/cytology , Glutamic Acid/metabolism , Green Fluorescent Proteins/genetics , Male , Membrane Potentials/drug effects , Membrane Potentials/physiology , Mice, Transgenic , Narcotics/administration & dosage , Narcotics/pharmacology , Nucleus Accumbens/cytology , Nucleus Accumbens/drug effects , Nucleus Accumbens/physiopathology , Piperidines/administration & dosage , Piperidines/pharmacology , Receptors, Opioid, mu/agonists , Receptors, Opioid, mu/metabolism , Remifentanil , Self Administration
8.
Psychopharmacology (Berl) ; 229(3): 527-38, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23748383

ABSTRACT

RATIONALE: Problematic drug use is associated with difficulty in exerting self-control over behaviors, and this difficulty may be a consequence of atypical morphometric characteristics that are exhibited by drug-experienced individuals. The extent to which these structural abnormalities result from drug use or reflect neurobiological risk factors that predate drug use, however, is unknown. OBJECTIVES: The purpose of this study is to determine how methamphetamine affects corticostriatal structure and how drug-induced changes relate to alterations in inhibitory control. METHODS: Structural magnetic resonance images and positron emission tomography (PET) scans, assessing dopamine D2-like receptor and transporter availability, were acquired in monkeys trained to acquire, retain, and reverse three-choice visual discrimination problems before and after exposure to an escalating dose regimen of methamphetamine (or saline, as a control). Voxel-based morphometry was used to compare changes in corticostriatal gray matter between methamphetamine- and saline-exposed monkeys. The change in gray matter before and after the dosing regimen was compared to the change in the behavioral performance and in dopaminergic markers measured with PET. RESULTS: Methamphetamine exposure, compared to saline, increased gray matter within the right putamen. These changes were positively correlated with changes in performance of methamphetamine-exposed monkeys in the reversal phase, and were negatively correlated with alterations in D2-like receptor and DAT availability. CONCLUSIONS: The results provide the first evidence that exposure to a methamphetamine dosing regimen that resembles human use alters the structural integrity of the striatum and that gray-matter abnormalities detected in human methamphetamine users are due, at least in part, to the pharmacological effects of drug experience.


Subject(s)
Amphetamine-Related Disorders/pathology , Amphetamine-Related Disorders/psychology , Inhibition, Psychological , Methamphetamine/pharmacology , Putamen/drug effects , Amphetamine-Related Disorders/metabolism , Animals , Chlorocebus aethiops , Cognition/drug effects , Discrimination, Psychological/drug effects , Dose-Response Relationship, Drug , Magnetic Resonance Imaging , Male , Methamphetamine/administration & dosage , Positron-Emission Tomography , Putamen/diagnostic imaging , Putamen/metabolism , Putamen/pathology , Receptors, Dopamine D2/metabolism , Retention, Psychology/drug effects , Reversal Learning/drug effects , Time Factors
9.
Biol Psychiatry ; 73(8): 756-62, 2013 Apr 15.
Article in English | MEDLINE | ID: mdl-23332512

ABSTRACT

BACKGROUND: The compulsive and inflexible behaviors that are present in many psychiatric disorders, particularly behavioral addictions and obsessive-compulsive disorder, may be due to neurochemical dysfunction within the circuitry that enables goal-directed behaviors. Experimental removal of serotonin or dopamine within the orbitofrontal cortex or dorsal striatum, respectively, impairs flexible responding in a reversal learning test, suggesting that these neurochemical systems exert important modulatory influences on goal-directed behaviors. Nevertheless, the behavioral impairments present in psychiatric disorders are likely due to subtle neurochemical differences, and it remains unknown whether naturally occurring variation in neurochemical levels associate with individual differences in flexible, reward-directed behaviors. METHODS: The current study assessed the ability of 24 individual juvenile monkeys to acquire, retain, and reverse discrimination problems and examined whether monoamine levels in the orbitofrontal cortex, caudate nucleus, and putamen could explain variance in behavior. RESULTS: The interaction between dopamine levels in the putamen and serotonin levels in the orbitofrontal cortex explained 61% of the variance in a measure of behavioral flexibility but not measures of associative learning or memory. The interaction mirrored that of a hyperbolic function, with reversal learning performance being poorest in either monkeys with relatively low levels of orbitofrontal serotonin and putamen dopamine or in monkeys with relatively high levels of orbitofrontal serotonin and putamen dopamine levels. CONCLUSIONS: These results support the hypothesis that subcortical and cortical neuromodulatory systems interact to guide aspects of goal-directed behavior, providing insight into the neurochemical dysfunction that may underlie the inflexible and compulsive behaviors present in psychiatric disorders.


Subject(s)
Dopamine/physiology , Frontal Lobe/physiology , Putamen/physiology , Reversal Learning/physiology , Serotonin/physiology , Animals , Caudate Nucleus/metabolism , Caudate Nucleus/physiology , Chlorocebus aethiops , Discrimination Learning/physiology , Dopamine/metabolism , Frontal Lobe/metabolism , Male , Putamen/metabolism , Serotonin/metabolism
10.
Neuropsychopharmacology ; 35(8): 1797-806, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20375994

ABSTRACT

The tendency for some individuals to partake in high-risk behaviors (eg, substance abuse, gambling, risky sexual activities) is a matter of great public health concern, yet the characteristics and neural bases of this vulnerability are largely unknown. Recent work shows that this susceptibility can be partially predicted by laboratory measures of reward seeking under risk, including the Balloon Analog Risk Task. Rats were trained to respond on two levers: one of which (the 'add lever') increased the size of a potential food reward and a second (the 'cash-out lever') that led to delivery of accrued reward. Crucially, each add-lever response was also associated with a risk that the trial would fail and no reward would be delivered. The relative probabilities that each add-lever press would lead to an addition food pellet or to trial failure (risk) were orthogonally varied. Rats exhibited a pattern of responding characteristic of incentive motivation and risk aversion, with a subset of rats showing traits of high-risk taking and/or suboptimal responding. Neural inactivation studies suggest that the orbitofrontal cortex supports greater reward seeking in the presence or absence of risk, whereas the medial prefrontal cortex is required for optimization of patterns of responding. These findings provide new information about the neural circuitry of decision making under risk and reveal new insights into the biological determinants of risk-taking behaviors that may be useful in developing biomarkers of vulnerability.


Subject(s)
Behavior, Animal/physiology , Conditioning, Operant/physiology , Decision Making/physiology , Prefrontal Cortex/physiology , Reward , Risk-Taking , Analysis of Variance , Animals , Baclofen/pharmacology , Behavior, Animal/drug effects , Conditioning, Operant/drug effects , Drug Combinations , GABA Agonists/pharmacology , Male , Muscimol/pharmacology , Prefrontal Cortex/drug effects , Probability , Rats , Rats, Long-Evans
11.
Neuropsychopharmacology ; 34(12): 2601-8, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19641486

ABSTRACT

Behavioral genetic studies of humans have associated variation in the DTNBP1 gene with schizophrenia and its cognitive deficit phenotypes. The protein coded for by DTNBP1, dysbindin, is expressed within forebrain glutamatergic neurons, in which it interacts with proteins involved in vesicular trafficking and exocytosis. In order to further delineate the cellular, physiological, and behavioral phenotypes associated with reduced dysbindin expression, we conducted studies in mice carrying a null mutation within the dtnbp1 gene. Dysbindin mutants showed impairments of spatial working memory compared with wild-type controls; heterozygous mice showed intermediate levels of cognitive dysfunction. Deep-layer pyramidal neurons recorded in the prefrontal cortex of mutant mice showed reductions in paired-pulse facilitation, and evoked and miniature excitatory post-synaptic currents, indicating a difference in the function of pre-synaptic glutamatergic terminals as well as elevated spike thresholds. Taken together, these data indicate that dysbindin potently regulates excitatory transmission in the prefrontal cortex, potentially through a pre-synaptic mechanism, and consequently modulates cognitive functions depending on this brain region, providing new insights into the molecular mechanisms underlying cortical dysfunction in schizophrenia.


Subject(s)
Carrier Proteins/metabolism , Glutamic Acid/metabolism , Memory, Short-Term/physiology , Prefrontal Cortex/physiology , Animals , Carrier Proteins/genetics , Dysbindin , Dystrophin-Associated Proteins , Evoked Potentials/physiology , Excitatory Postsynaptic Potentials/physiology , Male , Membrane Potentials/physiology , Memory Disorders/metabolism , Mice , Mice, Inbred DBA , Mice, Knockout , Neural Pathways/physiology , Neuropsychological Tests , Presynaptic Terminals/physiology , Pyramidal Cells/physiology , Space Perception/physiology , Synapses/physiology , Synaptic Transmission/physiology
12.
Neuropsychopharmacology ; 32(10): 2125-34, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17299511

ABSTRACT

Converging evidence supports a role for mesocorticolimbic dopaminergic systems in a subject's ability to shift behavior in response to changing stimulus-reward contingencies. To characterize the dopaminergic mechanisms involved in this function, we quantified the effects of subtype-specific dopamine (DA) receptor antagonists on acquisition, retention, and reversal of a visual discrimination task in non-human primates (Chlorocebus aethiops sabaeus). We used a modified Wisconsin General Test Apparatus that was equipped with three food boxes, each fitted with a lid bearing a unique visual cue; one of the cues concealed a food reward, whereas the other two concealed an empty box. The monkeys were trained first to acquire a novel discrimination (eg A(+), B(-), C(-)) in a single session, before experiencing either a reversal of the discrimination (eg A(-), B(+), C(-)) or the acquisition of a completely new discrimination (eg D(+), E(-), F(-)), on the following day. Systemic administration of the D(2)/D(3) receptor antagonist raclopride (0.001-0.03 mg/kg) failed to significantly affect the performance of reversal learning when reversal sessions were run without a retention session. But, raclopride (0.03 mg/kg) significantly impaired performance under the reversal condition when reversal sessions were run right after a retention session; however, it did not affect acquisition of a novel visual discrimination. Specifically, raclopride significantly increased the number of reversal errors made before reaching the performance criterion in the reversal, but not in new learning sessions. In contrast, the D(1)/D(5) receptor antagonist SCH 23390 did not significantly modulate acquisition of a novel discrimination or reversal learning at doses (0.001-0.03 mg/kg, i.m.) that did not suppress behavior generally. In addition, none of the drug treatments affected retention of a previously learned discrimination. The results strongly suggest that D(2)/D(3) receptors, but not D(1)/D(5) receptors, selectively mediate reversal learning, without affecting the capacity to learn a new stimulus-reward association. These data support the hypothesis that phasic DA release, acting through D(2)-like receptors, mediates behavioral flexibility.


Subject(s)
Brain/metabolism , Discrimination Learning/physiology , Dopamine/metabolism , Pattern Recognition, Visual/physiology , Receptors, Dopamine D2/metabolism , Receptors, Dopamine D3/metabolism , Animals , Behavior, Animal/drug effects , Behavior, Animal/physiology , Benzazepines/pharmacology , Brain/drug effects , Chlorocebus aethiops , Discrimination Learning/drug effects , Dopamine Antagonists/pharmacology , Dopamine D2 Receptor Antagonists , Dose-Response Relationship, Drug , Male , Neuropsychological Tests , Pattern Recognition, Visual/drug effects , Photic Stimulation , Raclopride/pharmacology , Receptors, Dopamine D1/antagonists & inhibitors , Receptors, Dopamine D1/metabolism , Receptors, Dopamine D3/antagonists & inhibitors
SELECTION OF CITATIONS
SEARCH DETAIL